AGIO
Price
$40.41
Change
+$0.42 (+1.05%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
2.34B
13 days until earnings call
IDYA
Price
$22.09
Change
-$0.06 (-0.27%)
Updated
Jul 17 closing price
Capitalization
1.93B
25 days until earnings call
Interact to see
Advertisement

AGIO vs IDYA

Header iconAGIO vs IDYA Comparison
Open Charts AGIO vs IDYABanner chart's image
Agios Pharmaceuticals
Price$40.41
Change+$0.42 (+1.05%)
Volume$23.2K
Capitalization2.34B
IDEAYA Biosciences
Price$22.09
Change-$0.06 (-0.27%)
Volume$684.62K
Capitalization1.93B
AGIO vs IDYA Comparison Chart in %
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. IDYA commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a StrongBuy and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (AGIO: $39.99 vs. IDYA: $22.15)
Brand notoriety: AGIO and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 103% vs. IDYA: 55%
Market capitalization -- AGIO: $2.34B vs. IDYA: $1.93B
AGIO [@Biotechnology] is valued at $2.34B. IDYA’s [@Biotechnology] market capitalization is $1.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • AGIO’s TA Score: 4 bullish, 4 bearish.
  • IDYA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AGIO is a better buy in the short-term than IDYA.

Price Growth

AGIO (@Biotechnology) experienced а +2.35% price change this week, while IDYA (@Biotechnology) price change was -3.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.05%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +40.92%.

Reported Earning Dates

AGIO is expected to report earnings on Jul 31, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+2.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($2.34B) has a higher market cap than IDYA($1.94B). AGIO YTD gains are higher at: 21.698 vs. IDYA (-13.813). IDYA has higher annual earnings (EBITDA): -356.46M vs. AGIO (-434.71M). AGIO has more cash in the bank: 893M vs. IDYA (693M). IDYA has less debt than AGIO: IDYA (26M) vs AGIO (52.9M). AGIO has higher revenues than IDYA: AGIO (37M) vs IDYA (7M).
AGIOIDYAAGIO / IDYA
Capitalization2.34B1.94B121%
EBITDA-434.71M-356.46M122%
Gain YTD21.698-13.813-157%
P/E Ratio3.50N/A-
Revenue37M7M529%
Total Cash893M693M129%
Total Debt52.9M26M203%
FUNDAMENTALS RATINGS
AGIO vs IDYA: Fundamental Ratings
AGIO
IDYA
OUTLOOK RATING
1..100
1559
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
1794
PRICE GROWTH RATING
1..100
4258
P/E GROWTH RATING
1..100
62100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (43) in the Biotechnology industry is in the same range as IDYA (61) in the null industry. This means that AGIO’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (88) in the null industry is in the same range as AGIO (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for IDYA (94) in the null industry. This means that AGIO’s stock grew significantly faster than IDYA’s over the last 12 months.

AGIO's Price Growth Rating (42) in the Biotechnology industry is in the same range as IDYA (58) in the null industry. This means that AGIO’s stock grew similarly to IDYA’s over the last 12 months.

AGIO's P/E Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for IDYA (100) in the null industry. This means that AGIO’s stock grew somewhat faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOIDYA
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 18 days ago
76%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSLCX39.250.37
+0.95%
Hartford Small Cap Growth C
NTIAX14.390.07
+0.49%
Columbia Mid Cap Index A
AHSCX11.170.04
+0.36%
Alger Health Sciences C
RGLAX26.330.04
+0.15%
American Funds Global Insight R-1
FHJTX43.48N/A
N/A
Fidelity Advisor Europe C

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with LGND. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then LGND could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
+2.04%
LGND - AGIO
53%
Loosely correlated
+4.29%
ZYME - AGIO
49%
Loosely correlated
+4.97%
IDYA - AGIO
48%
Loosely correlated
+3.36%
OCUL - AGIO
47%
Loosely correlated
+1.44%
CRNX - AGIO
47%
Loosely correlated
+0.22%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+3.36%
IMNM - IDYA
62%
Loosely correlated
+15.12%
DNLI - IDYA
60%
Loosely correlated
+4.94%
NRIX - IDYA
60%
Loosely correlated
+2.22%
XENE - IDYA
60%
Loosely correlated
+0.44%
CRNX - IDYA
59%
Loosely correlated
+0.22%
More